Use of medication for challenging behaviour in people with intellectual disability

British Journal of Psychiatry

Volumn 205, Issue 1, 2014, Pages 6-7

  Glover, Gyles ^a   Bernard, Sarah ^b   Branford, David ^c   Holland, Anthony ^d   Strydom, Andre ^e  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL PHARMACEUTICAL SOCIETY   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; DRUG INDICATION; HUMAN; INTELLECTUAL IMPAIRMENT; MENTAL DISEASE; MOOD DISORDER; OFF LABEL DRUG USE; PHARMACEUTICAL CARE; RESIDENTIAL CARE; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; HUMANS; INTELLECTUAL DISABILITY; OFF-LABEL USE;

EID: 84904022457     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.113.141267     Document Type: Review

References (12)

1. Department of Health. Transforming Care: A National Response to Winterbourne View Hospital. Department of Health Review: Final Report. Department of Health 2012
2. Royal College of Psychiatrists, British Psychological Society, Royal College of Speech and Language Therapists. Challenging Behaviour: A Unified Approach. Clinical and Service Guidelines for Supporting People with Learning Disabilities who are at Risk of Receiving Abusive or Restrictive Practices (College Report CR144). Royal College of Psychiatrists 2007
3. Paton C, Flynn A, Shingleton-Smith A, McIntyre S, Bhaumik S, Rasmussen J, et al. Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services. J Intellect Disabil Res 2011; 55: 665-74.
4. Emerson E, Einfeld SL (eds) Pharmacotherapy. In Challenging Behaviour (3rd edn): 94-101. Cambridge University Press 2011
5. Tyrer P, Oliver-Africano PC, Ahmed Z, Bouras N, Cooray S, Deb S, et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet 2008; 371: 57-63.
6. De Kuijper G, Evenhuis H, Minderaa RB, Hoekstra PY. Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. J Intellect Disabil Res 2014; 58: 71-83.
7. Joint Formulary Committee. British National Formulary (BNF) 67 (March- September 2014). Pharmacuetical Press 2014
8. Banerjee S. The Use of Antipsychotic Medication for People with Dementia: Time for Action. Department of Health 2009
9. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006; 166: 1021-6.
10. Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course. Arch Intern Med 2013; 169: 1745-7.
11. General Medical Council. Good Practice in Prescribing and Managing Medicines and Devices. GMC 2013
12. Menon K, Baburaj R, Bernard S. Use of restraint for the management of challenging behaviour in children with intellectual disabilities. Adv Ment Heal Intellect Disabil 2012; 6: 62-75.